Ruxolitinib for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 May 2025: Trial started, NCT07238712
  2. 20 Nov 2025: Trial registered, NCT07238712

The trials

NCT07238712: Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

State
Under way
Phase
Phase 2
People
80 planned
Started
10 May 2025
Primary completion
10 Dec 2027
Arms
Experimental: Test cohort 1 - ruxolitinib
Results
None posted
  1. 10 May 2025: Trial started
  2. 20 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Post-transplant Ruxolitinib, Ruxolitinib 5 MG.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.